• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

莫西沙星体外对专性厌氧菌的比较活性

Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.

作者信息

Ackermann G, Schaumann R, Pless B, Claros M C, Goldstein E J, Rodloff A C

机构信息

Institute for Medical Microbiology and Epidemiology of Infectious Diseases, University of Leipzig, Germany.

出版信息

Eur J Clin Microbiol Infect Dis. 2000 Mar;19(3):228-32. doi: 10.1007/s100960050465.

DOI:10.1007/s100960050465
PMID:10795599
Abstract

The antimicrobial activity of moxifloxacin and seven other antibiotics (four of them quinolones) against 292 strains of obligately anaerobic bacteria was assessed employing a broth microdilution technique performed in Wilkens-Chalgren broth. MIC50/MIC90 values (mg/l) for moxifloxacin were as follows: Bacteroides fragilis (n = 62) 0.25/2, Bacteroides ovatus (n = 70) 1/4, Bacteroides vulgatus (n = 29) 0.25/1, Bacteroides thetaiotaomicron (n = 17) 2/2, Bacteroides caccae (n = 11) 1/2, Prevotella spp. (n = 11) 0.25/2, Fusobacterium spp. (n = 17) 1/4, Bilophila wadsworthia (n = 29) 0.5/1, and Clostridium spp. (n = 29) 0.125/0.5, respectively. MIC50 values (mg/l) for Bacteroides distasonis (n = 8) and Peptostreptococcus spp. (n = 9) were 0.25. The results indicated that moxifloxacin was almost as active as trovafloxacin, as active as gatifloxacin, and more active than levofloxacin and ciprofloxacin against the anaerobes tested.

摘要

采用在威尔肯斯 - 查尔格伦肉汤中进行的肉汤微量稀释技术,评估了莫西沙星和其他七种抗生素(其中四种为喹诺酮类)对292株专性厌氧菌的抗菌活性。莫西沙星的MIC50/MIC90值(mg/l)如下:脆弱拟杆菌(n = 62)为0.25/2,卵形拟杆菌(n = 70)为1/4,普通拟杆菌(n = 29)为0.25/1,多形拟杆菌(n = 17)为2/2,粪拟杆菌(n = 11)为1/2,普雷沃菌属(n = 11)为0.25/2,梭杆菌属(n = 17)为1/4,沃兹沃思嗜胆菌(n = 29)为0.5/1,梭菌属(n = 29)为0.125/0.5。解脲拟杆菌(n = 8)和消化链球菌属(n = 9)的MIC50值(mg/l)为0.25。结果表明,在测试针对厌氧菌方面,莫西沙星的活性几乎与曲伐沙星相同,与加替沙星相当,且比左氧氟沙星和环丙沙星更具活性。

相似文献

1
Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.莫西沙星体外对专性厌氧菌的比较活性
Eur J Clin Microbiol Infect Dis. 2000 Mar;19(3):228-32. doi: 10.1007/s100960050465.
2
In vitro activity of telithromycin (HMR 3647) and seven other antimicrobial agents against anaerobic bacteria.替利霉素(HMR 3647)及其他七种抗菌药物对厌氧菌的体外活性
J Antimicrob Chemother. 2000 Jul;46(1):115-9. doi: 10.1093/jac/46.1.115.
3
In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.曲伐沙星对557株厌氧菌的体外活性
Antimicrob Agents Chemother. 1996 Sep;40(9):2232-5. doi: 10.1128/AAC.40.9.2232.
4
Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.BAY 12 - 8039与其他五种抗菌剂对厌氧菌的体外活性比较
Eur J Clin Microbiol Infect Dis. 1998 Mar;17(3):193-5. doi: 10.1007/BF01691117.
5
In vitro activity of gemifloxacin (SB 265805) against anaerobes.吉米沙星(SB 265805)对厌氧菌的体外活性。
Antimicrob Agents Chemother. 1999 Sep;43(9):2231-5. doi: 10.1128/AAC.43.9.2231.
6
Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.ABT-773对362株厌氧菌临床分离株的体外活性比较
Antimicrob Agents Chemother. 2001 Jan;45(1):345-8. doi: 10.1128/AAC.45.1.345-348.2001.
7
In vitro activity of BAY 12-8039, a new fluoroquinolone.新型氟喹诺酮类药物BAY 12 - 8039的体外活性
Antimicrob Agents Chemother. 1997 Jan;41(1):101-6. doi: 10.1128/AAC.41.1.101.
8
Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria.Bay 12 - 8039,一种新型8 - 甲氧基喹诺酮:与其他九种抗菌药物对厌氧菌的体外活性比较
J Antimicrob Chemother. 1997 Oct;40(4):503-9. doi: 10.1093/jac/40.4.503.
9
Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.新型氯氟喹诺酮BAY y 3118与环丙沙星、司帕沙星及其他抗菌药物相比,对厌氧菌的活性增强。
Antimicrob Agents Chemother. 1994 Jul;38(7):1671-4. doi: 10.1128/AAC.38.7.1671.
10
In vitro activity of Bay Y3118 against anaerobic bacteria.Bay Y3118对厌氧菌的体外活性。
Antimicrob Agents Chemother. 1993 Nov;37(11):2509-13. doi: 10.1128/AAC.37.11.2509.

引用本文的文献

1
Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials.莫西沙星治疗继发性腹膜炎住院患者的疗效与安全性:四项随机III期试验的汇总分析
Surg Infect (Larchmt). 2014 Oct;15(5):567-75. doi: 10.1089/sur.2013.045. Epub 2014 May 15.
2
Relapse of posttraumatic osteomyelitis due to Clostridium celerecrescens.由迅速复活梭菌引起的创伤后骨髓炎复发。
Infection. 2011 Oct;39(5):491-4. doi: 10.1007/s15010-011-0125-5. Epub 2011 Jun 7.
3
Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
艰难梭菌PCR核糖体分型027和001在人体肠道模型中暴露于氟喹诺酮类药物的影响。
Antimicrob Agents Chemother. 2009 Feb;53(2):412-20. doi: 10.1128/AAC.00306-08. Epub 2008 Aug 18.
4
Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: a pilot study.莫西沙星与阿莫西林/克拉维酸治疗严重牙源性脓肿的临床及微生物学疗效:一项前瞻性研究。
Eur J Clin Microbiol Infect Dis. 2009 Jan;28(1):75-82. doi: 10.1007/s10096-008-0587-2. Epub 2008 Jul 29.
5
Activity of pradofloxacin against Porphyromonas and Prevotella spp. Implicated in periodontal disease in dogs: susceptibility test data from a European multicenter study.普拉德氟沙星对犬牙周疾病相关卟啉单胞菌属和普雷沃菌属的活性:一项欧洲多中心研究的药敏试验数据
Antimicrob Agents Chemother. 2008 Jun;52(6):2149-55. doi: 10.1128/AAC.00019-08. Epub 2008 Apr 14.
6
Moxifloxacin in the treatment of skin and skin structure infections.莫西沙星治疗皮肤和皮肤结构感染。
Ther Clin Risk Manag. 2006 Dec;2(4):417-34. doi: 10.2147/tcrm.2006.2.4.417.
7
Acute cholecystitis - early laparoskopic surgery versus antibiotic therapy and delayed elective cholecystectomy: ACDC-study.急性胆囊炎——早期腹腔镜手术与抗生素治疗及延迟择期胆囊切除术:一项ACDC研究
Trials. 2007 Oct 4;8:29. doi: 10.1186/1745-6215-8-29.
8
Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials : results of a two-year study.抗生素治疗慢性阻塞性肺疾病急性加重后恢复速度:一项为期两年的研究结果。
Clin Drug Investig. 2003;23(7):439-50. doi: 10.2165/00044011-200323070-00003.
9
Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany.在德国一项大型队列研究中,莫西沙星在慢性支气管炎急性加重症的日常治疗中的应用。
Clin Drug Investig. 2004;24(8):449-55. doi: 10.2165/00044011-200424080-00003.
10
Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources.从各种人类来源分离出的厌氧消化链球菌和新描述的口腔消化链球菌的抗菌药敏性。
Antimicrob Agents Chemother. 2007 Jun;51(6):2205-7. doi: 10.1128/AAC.00056-07. Epub 2007 Apr 2.